Third, we showed that increased 4R tau is sufficient to drive this pathogenic cascade in control human excitatory cortical neurons, suggesting that it might be a viable therapeutic candidate for VCP mutation-related FTD. This evidence concerns the gene MAPT and frontotemporal dementia.